By admin 
The landscape of pediatric oncology is poised for a significant shift as CureSearch for Children’s Cancer officially announces the recipient of its prestigious 2026 CureSearch Catapult Award. Dr. Robbie Majzner, a distinguished researcher at the Dana-Farber Cancer Institute, has been awarded a $2 million investment to spearhead a Phase I clinical trial for a revolutionary CAR T-cell therapy. This funding, co-sponsored by the Jeff Gordon Children’s Foundation, aims to address one of the most persistent and lethal challenges in pediatric medicine: relapsed and refractory neuroblastoma. By targeting the "Valley of Death"—the notorious gap between laboratory discovery and clinical application—this award provides the necessary resources to move a high-potential biological innovation into the hospital setting, where it can directly impact the lives of children and young adults who have exhausted traditional treatment options.
The Critical Challenge of High-Risk Neuroblastoma
Neuroblastoma is a cancer that develops from immature nerve cells found in several areas of the body, most commonly arising in and around the adrenal glands. It is the most frequent extracranial solid tumor diagnosed in infants and young children, representing approximately 7% to 10% of all pediatric cancer cases. However, its impact on mortality is disproportionately high, accounting for more than 10% of all childhood cancer-related deaths.
For clinicians and families, the prognosis for high-risk neuroblastoma remains one of the most daunting figures in oncology. Despite aggressive multi-modal treatment strategies—including high-dose chemotherapy, surgical resection, radiation, and autologous stem cell transplants—the five-year survival rate for high-risk patients remains stubbornly below 50%. For those who experience a relapse or whose cancer is refractory (resistant) to initial treatment, the outlook is even more somber. Furthermore, the "cure" often comes at a heavy price; survivors frequently endure lifelong side effects, including hearing loss, cardiac complications, secondary malignancies, and significant developmental delays. The urgent need for targeted, less toxic, and more effective therapies has never been more apparent.
Bridging the Gap: The Catapult Award and the Valley of Death
The trajectory of medical innovation is often halted by a lack of funding for early-stage clinical trials. While fundamental laboratory research is frequently supported by government grants, and late-stage trials are often funded by pharmaceutical companies, the transition from a successful "bench" experiment to a "bedside" Phase I trial is notoriously difficult to finance. This phase is often referred to by researchers as the "Valley of Death."
The CureSearch Catapult Award was specifically designed to bridge this chasm. By providing substantial financial backing at this critical juncture, CureSearch ensures that the most promising scientific breakthroughs do not languish in academic journals but are instead tested in the clinical environment. The selection of Dr. Majzner for the 2026 award underscores the organization’s commitment to funding "bold science" that has the potential to redefine the standard of care for pediatric solid tumors.
The Evolution of CAR T-Cell Therapy: From Blood to Solid Tumors
Chimeric Antigen Receptor (CAR) T-cell therapy has already revolutionized the treatment of certain hematologic malignancies, such as B-cell acute lymphoblastic leukemia (ALL). This immunotherapy involves extracting a patient’s own T-cells—the "soldiers" of the immune system—and genetically engineering them to express a specific receptor that recognizes and kills cancer cells. Once these modified cells are infused back into the patient, they seek out and destroy the malignancy.
However, replicating the success of CAR T-cells in solid tumors like neuroblastoma has proven exceptionally difficult. Unlike blood cancers, solid tumors create a hostile "microenvironment" that suppresses immune activity. Furthermore, solid tumors often lack unique markers that allow T-cells to distinguish between cancer and healthy tissue. One of the primary reasons for failure in previous neuroblastoma trials has been "T-cell exhaustion," a state where the engineered cells become overstimulated and lose their ability to multiply or attack the tumor, eventually becoming inactive.
Technical Innovation: The Role of GD2 and ZAP70
Dr. Majzner’s research at Dana-Farber seeks to solve the exhaustion problem through a sophisticated redesign of the CAR T-cell architecture. The therapy focuses on a molecule called GD2, a sugar-fat compound (disialoganglioside) that is expressed at very high levels on the surface of nearly all neuroblastoma cells. While GD2 has long been a target for monoclonal antibodies, Dr. Majzner’s team is taking the approach to a more advanced cellular level.
The innovation lies in the incorporation of a novel signaling protein known as ZAP70. In a natural immune response, ZAP70 plays a crucial role in relaying signals from the T-cell receptor to the rest of the cell, orchestrating a sustained and controlled attack. By integrating ZAP70 into the synthetic CAR structure, Dr. Majzner’s team has created a "next-generation" CAR T-cell.
In preclinical models, these redesigned cells have shown a remarkable ability to remain active for longer periods. By resisting exhaustion, the cells can sustain their anti-tumor pressure, potentially leading to the complete eradication of the cancer rather than a temporary reduction. Additionally, the new architecture appears to offer a more favorable safety profile, reducing the risk of "off-target" effects that have plagued previous iterations of GD2-targeted therapies.
Chronology of Development and the Upcoming Phase I Trial
The path to the 2026 Catapult Award has been paved by years of rigorous laboratory investigation. Dr. Majzner, who recently moved his laboratory to Dana-Farber Cancer Institute, has long been a pioneer in the field of pediatric immunotherapy.
- Discovery Phase: Researchers identified the specific signaling limitations of first- and second-generation CAR T-cells when facing the dense, immunosuppressive environment of solid tumors.
- Engineering Phase: The team utilized synthetic biology to test various signaling domains, eventually identifying ZAP70 as a key component for improving T-cell persistence and potency.
- Preclinical Validation: Extensive testing in laboratory "in vitro" models and "in vivo" mouse models demonstrated that the ZAP70-enhanced CAR T-cells were significantly more effective at shrinking neuroblastoma tumors than standard CAR T-cells.
- The Catapult Award (Current Stage): With the $2 million investment, the team is now transitioning into the clinical phase.
- Phase I Clinical Trial: This upcoming study will be the first time this specific ZAP70-augmented therapy is administered to humans. The primary objectives will be to determine the safety of the treatment, establish the optimal dosage, and observe preliminary signs of efficacy in children and young adults with relapsed or refractory neuroblastoma.
Statements from Leadership and Scientific Community
The announcement has been met with significant optimism from both the philanthropic and scientific communities. Dr. Robbie Majzner emphasized the necessity of this funding in moving the needle for pediatric patients.
"Current GD2 CAR T cells only work in patients with small amounts of disease. We’ve designed a brand-new CAR architecture that breaks past limitations to success in lab models, and this trial will allow us to bring this advanced therapy to the children who need it most," Dr. Majzner stated. He further noted that the Catapult Award serves as the essential "momentum" required to move science from the laboratory "directly to the forefront of patient care."
Dr. Paisley Myers, Senior Director of Research & Programs at CureSearch, highlighted the strategic importance of the award. "One of the greatest challenges in pediatric cancer research is ensuring that promising discoveries reach children," she said. "Through the Catapult Award, CureSearch helps move innovative therapies from the laboratory into clinical trials. Dr. Majzner’s work exemplifies the bold, high-potential research we were created to support."
The collaboration with the Jeff Gordon Children’s Foundation also highlights a growing trend in pediatric oncology: the necessity of multi-organizational partnerships to fund high-cost, high-reward clinical research that might otherwise be overlooked by traditional commercial interests.
Broader Implications for Oncology and Immunotherapy
The success of this Phase I trial could have implications that reach far beyond neuroblastoma. GD2 is not only found in neuroblastoma but is also expressed in several other difficult-to-treat pediatric and adult cancers, including osteosarcoma (a common bone cancer), melanoma, and certain types of brain tumors like diffuse intrinsic pontine glioma (DIPG).
If Dr. Majzner’s ZAP70-enhanced CAR T-cells prove effective in overcoming T-cell exhaustion in neuroblastoma, this "blueprint" could be applied to a wide array of other solid tumors. This would mark a paradigm shift in immunotherapy, moving it away from being a treatment primarily for "liquid" blood cancers and establishing it as a viable weapon against the solid masses that constitute the majority of cancer diagnoses.
Furthermore, the study will provide invaluable data on the mechanics of T-cell persistence in humans. By analyzing how these modified cells behave within the patient’s body, researchers will gain insights into the complex interactions between the immune system and the tumor microenvironment, potentially leading to even more refined "third-generation" therapies in the future.
Conclusion: A New Era of Hope
As the medical community looks toward the start of the clinical trial, the focus remains on the children and families who are currently facing limited options. The $2 million investment by CureSearch and the Jeff Gordon Children’s Foundation is more than just a financial grant; it is a calculated bet on a scientific breakthrough that could change the definition of "terminal" for thousands of young patients.
By addressing the biological hurdles of T-cell exhaustion and the financial hurdles of early-stage clinical trials, the CureSearch Catapult Award is fulfilling its mission to accelerate the pace of pediatric cancer research. For Dr. Majzner and his team at Dana-Farber, the work is just beginning, but the goal remains clear: to ensure that the next generation of children diagnosed with neuroblastoma has access to a therapy that is as resilient and persistent as the patients themselves.
